74 related articles for article (PubMed ID: 438606)
1. A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combinations.
Danhauser LL; Rustum YM
J Lab Clin Med; 1979 Jun; 93(6):1047-53. PubMed ID: 438606
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacologic effects of thymidine plus 5-FU.
Ohnuma T; Roboz J; Waxman S; Mandel E; Martin DS; Holland JF
Cancer Treat Rep; 1980; 64(12):1169-77. PubMed ID: 7471111
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic efficacy of 5-fluorouracil with concurrent thymidine infusion against transplantable colon tumors in rodents.
Danhauser LL; Rustum YM
Cancer Drug Deliv; 1984; 1(4):269-82. PubMed ID: 6549560
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Chun H; Martin D; Young C
Cancer Treat Rep; 1985 Feb; 69(2):179-84. PubMed ID: 3971391
[TBL] [Abstract][Full Text] [Related]
6. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
7. [Experimental studies on the optimal therapeutic mode of intra-arterial infusion of 5-fluorouracil. (1) Preparation of an animal model for continuous intra-arterial infusion and comparison of the therapeutic and adverse effects of 5-fluorouracil delivered by various modes].
Ota J
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2353-61. PubMed ID: 6639097
[TBL] [Abstract][Full Text] [Related]
8. Enhancement by thymidine of 5-fluorouracil's inhibition of thymidylate synthetase in human tumors.
Wolberg WH
Cancer Treat Rep; 1979; 63(11-12):1817-20. PubMed ID: 526916
[TBL] [Abstract][Full Text] [Related]
9. Modulation of 5-FU action by thymidine in murine and human tumors.
Young CW; Woodcock TM; Martin DS
Cancer Treat Rep; 1981; 65 Suppl 3():83-7. PubMed ID: 7346156
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
11. Technique for preclinical evaluation of continuous infusion chemotherapy with the use of WF rat acute myelogenous leukemia.
Ensminger WD; Greenberger JS; Egan EM; Muse MB; Moloney WC
J Natl Cancer Inst; 1979 May; 62(5):1265-8. PubMed ID: 155752
[TBL] [Abstract][Full Text] [Related]
12. A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice.
Lee JM; Erlich RB; Bruckner HW; Szrajer L; Ohnuma T
Anticancer Res; 1993; 13(5A):1453-6. PubMed ID: 8239519
[TBL] [Abstract][Full Text] [Related]
13. [Experimental studies on the optimal therapeutic mode of intra-arterial infusion of 5-fluorouracil. (2) Concentrations within the tumors and normal tissues and therapeutic and adverse effects of 5-fluorouracil delivered by various routes].
Ota J
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2362-9. PubMed ID: 6639098
[TBL] [Abstract][Full Text] [Related]
14. Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.
Woodcock TM; Martin DS; Damin LA; Kemeny NE; Young CW
Cancer; 1980 Mar; 45(5 Suppl):1135-43. PubMed ID: 7357508
[TBL] [Abstract][Full Text] [Related]
15. Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
Oman M; Tölli J; Naredi P; Hafström LO
Cancer Chemother Pharmacol; 2004 Sep; 54(3):213-8. PubMed ID: 15138707
[TBL] [Abstract][Full Text] [Related]
16. Thymidine and 5-FU: a Phase II pilot study in colorectal and breast carcinomas.
Presant CA; Multhauf P; Klein L; Chan C; Chang FF; Hum G; Joseph R; Opfell R; Lemkin S; Shiftan T; Plotkin D
Cancer Treat Rep; 1983; 67(7-8):735-6. PubMed ID: 6871891
[No Abstract] [Full Text] [Related]
17. [An experimental study on portal infusion of 5-fluorouracil].
Ishida H; Iwama T; Nishioka Y; Endo S; Okubo Y; Imajo M; Otomo M; Mishima Y
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1884-8. PubMed ID: 1877831
[TBL] [Abstract][Full Text] [Related]
18. [Clinical reevaluation of continuous intravenous infusion of 5-fluorouracil--plasma concentrations and clinical dose by continuous intravenous and 60-min infusions].
Nakatsu T; Yokoyama I; Tsuyuki K; Soh Y; Hanai G; Matsumoto H; Kubo H; Matsumoto K; Nohga K; Koyanagi H
Gan To Kagaku Ryoho; 1990 Feb; 17(2):253-8. PubMed ID: 2301952
[TBL] [Abstract][Full Text] [Related]
19. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
